Ivosidenib Access Program for Patients with Relapsed or Hard-to-Treat AML with an IDH1 Mutation | Clinical Trial

Ivosidenib Access Program for Patients with Relapsed or Hard-to-Treat AML with an IDH1 Mutation | Clinical Trial | Right2Hope